OncoMatch/Clinical Trials/NCT07020221
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Official title: A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors
Is NCT07020221 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies multiple treatments for pancreatic ductal adenocarcinoma.
Treatment: VS-7375 · Cetuximab · Carboplatin + Pemetrexed + Pembrolizumab · Gemcitabine + Nab-paclitaxel · Pembrolizumab · Defactinib · Midazolam · Repaglinide — This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS g12d
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: direct RAS inhibitor
History of treatment with direct RAS inhibitors.
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cedars-Sinai Medical Center · Los Angeles, California
- Johns Hopkins University · Baltimore, Maryland
- Massachusetts General Hospital · Boston, Massachusetts
- University of Michigan · Ann Arbor, Michigan
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07020221 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior direct RAS inhibitor disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS g12d is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify